Drug Absorption Efficiency in Caenorhbditis elegans Delivered by Different Methods

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Zheng, Shan Qing ^a,b   Ding, Ai Jun ^a,b   Li, Guo Ping ^c   Wu, Gui Sheng ^d   Luo, Huai Rong ^a  

^a KUNMING INSTITUTE OF BOTANY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c BEIJING HOSPITAL   (China)

^d KUNMING INSTITUTE OF ZOOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FLOXURIDINE; RESVERATROL;

ARTICLE; CAENORHABDITIS ELEGANS; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG METABOLISM; DRUG SOLUBILITY; DRUG SOLUTION; ESCHERICHIA COLI; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LB MEDIUM METHOD; LIQUID GROWING METHOD; NEMATODE GROWTH MEDIUM DEAD METHOD; NEMATODE GROWTH MEDIUM LIVE METHOD; NONHUMAN; SPOT DEAD METHOD;

ABSORPTION; ANIMALS; CAENORHABDITIS ELEGANS; SOLUBILITY; STILBENES;

EID: 84874548073     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056877     Document Type: Article

References (50)

1. Brenner S, (1974) The genetics of Caenorhabditis elegans. Genetics 77: 71-94.
2. Artal-Sanz M, de Jong L, Tavernarakis N, (2006) Caenorhabditis elegans: a versatile platform for drug discovery. Biotechnol J 1: 1405-1418.
3. Burns AR, Kwok TC, Howard A, Houston E, Johanson K, et al. (2006) High-throughput screening of small molecules for bioactivity and target identification in Caenorhabditis elegans. Nat Protoc 1: 1906-1914.
4. Kim S, Paik YK, (2008) Developmental and reproductive consequences of prolonged non-aging dauer in Caenorhabditis elegans. Biochem Biophys Res Commun 368: 588-592.
5. Kimble J, Hirsh D, (1979) The postembryonic cell lineages of the hermaphrodite and male gonads in Caenorhabditis elegans. Dev Biol 70: 396-417.
6. Boehm M, Slack F, (2005) A developmental timing microRNA and its target regulate life span in C. elegans. Science 310: 1954-1957.
7. Kniazeva M, Sieber M, McCauley S, Zhang K, Watts JL, et al. (2003) Suppression of the ELO-2 FA elongation activity results in alterations of the fatty acid composition and multiple physiological defects, including abnormal ultradian rhythms, in Caenorhabditis elegans. Genetics 163: 159-169.
8. Kniazeva M, Crawford QT, Seiber M, Wang CY, Han M, (2004) Monomethyl branched-chain fatty acids play an essential role in Caenorhabditis elegans development. PLoS Biol 2.
9. Zheng J, Greenway FL, (2012) Caenorhabditis elegans as a model for obesity research. Int J Obes (Lond) 36: 186-194.
10. Johnson TE, Wood WB, (1982) Genetic analysis of life-span in Caenorhabditis elegans. Proc Natl Acad Sci U S A 79: 6603-6607.
11. Jones DL, Rando TA, (2011) Emerging models and paradigms for stem cell ageing. Nat Cell Biol 13: 506-512.
12. Nass R, Miller DM, Blakely RD, (2001) C. elegans: a novel pharmacogenetic model to study Parkinson's disease. Parkinsonism Relat Disord 7: 185-191.
13. Levitan D, Greenwald I, (1995) Facilitation of lin-12-mediated signalling by sel-12, a Caenorhabditis elegans S182 Alzheimer's disease gene. Nature 377: 351-354.
14. Dexter PM, Caldwell KA, Caldwell GA, (2012) A predictable worm: application of Caenorhabditis elegans for mechanistic investigation of movement disorders. Neurotherapeutics 9: 393-404.
15. Moy TI, Ball AR, Anklesaria Z, Casadei G, Lewis K, et al. (2006) Identification of novel antimicrobials using a live-animal infection model. Proc Natl Acad Sci U S A 103: 10414-10419.
16. Desalermos A, Muhammed M, Glavis-Bloom J, Mylonakis E, (2011) Using C. elegans for antimicrobial drug discovery. Expert Opin Drug Discov 6: 645-652.
17. Anastassopoulou CG, Fuchs BB, Mylonakis E, (2011) Caenorhabditis elegans-based model systems for antifungal drug discovery. Curr Pharm Des 17: 1225-1233.
18. Sifri CD, Begun J, Ausubel FM, (2005) The worm has turned-microbial virulence modeled in Caenorhabditis elegans. Trends Microbiol 13: 119-127.
19. Leung MC, Williams PL, Benedetto A, Au C, Helmcke KJ, et al. (2008) Caenorhabditis elegans: an emerging model in biomedical and environmental toxicology. Toxicol Sci 106: 5-28.
20. Sellers WR, (2011) A blueprint for advancing genetics-based cancer therapy. Cell 147: 26-31.
21. Onken B, Driscoll M, (2010) Metformin induces a dietary restriction-like state and the oxidative stress response to extend C. elegans Healthspan via AMPK, LKB1, and SKN-1. PLoS One 5: e8758.
22. Evason K, Collins JJ, Huang C, Hughes S, Kornfeld K, (2008) Valproic acid extends Caenorhabditis elegans lifespan. Aging Cell 7: 305-317.
23. Stiernagle T, (2006) Maintenance of C. elegans. WormBook pp. 1-11.
24. Evason K, Huang C, Yamben I, Covey DF, Kornfeld K, (2005) Anticonvulsant medications extend worm life-span. Science 307: 258-262.
25. Petrascheck M, Ye X, Buck LB, (2007) An antidepressant that extends lifespan in adult Caenorhabditis elegans. Nature 450: 553-556.
26. Melov S, Ravenscroft J, Malik S, Gill MS, Walker DW, et al. (2000) Extension of life-span with superoxide dismutase/catalase mimetics. Science 289: 1567-1569.
27. Zarse K, Ristow M, (2008) Antidepressants of the serotonin-antagonist type increase body fat and decrease lifespan of adult Caenorhabditis elegans. PLoS One 3: e4062.
28. Keaney M, Gems D, (2003) No increase in lifespan in Caenorhabditis elegans upon treatment with the superoxide dismutase mimetic EUK-8. Free Radical Biology and Medicine 34: 277-282.
29. Burns AR, Wallace IM, Wildenhain J, Tyers M, Giaever G, et al. (2010) A predictive model for drug bioaccumulation and bioactivity in Caenorhabditis elegans. Nat Chem Biol 6: 549-557.
30. Wood JG, Rogina B, Lavu S, Howitz K, Helfand SL, et al. (2004) Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 430: 686-689.
31. Guarente L, (2005) Calorie restriction and SIR2 genes-towards a mechanism. Mech Ageing De 126: 923-928.
32. Kaeberlein M, McDonagh T, Heltweg B, Hixon J, Westman EA, et al. (2005) Substrate-specific activation of sirtuins by resveratrol. J Biol Chem 280: 17038-17045.
33. Park SJ, Ahmad F, Philp A, Baar K, Williams T, et al. (2012) Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148: 421-433.
34. Mitchell DH, Stiles JW, Santelli J, Sanadi DR, (1978) Synchronous growth and aging of Caenorhabditis elegans in the presence of fluorodeoxyuridine. J Gerontol 34: 28-36.
35. Gandhi S, Santelli J, Mitchell DH, Stiles JW, et al. (1980) A simple method for maintaining large, aging populations of Caenorhabditis elegans. Mechanisms of Ageing and Development 12 (2):: 137-150.
36. Tevell Aberg A, Lofgren H, Bondesson U, Hedeland M, (2010) Structural elucidation of N-oxidized clemastine metabolites by liquid chromatography/tandem mass spectrometry and the use of Cunninghamella elegans to facilitate drug metabolite identification. Rapid Commun Mass Spectrom 24: 1447-1456.
37. Wypijewska A, Bojarska E, Stepinski J, Jankowska-Anyszka M, Jemielity J, et al. (2010) Structural requirements for Caenorhabditis elegans DcpS substrates based on fluorescence and HPLC enzyme kinetic studies. FEBS J 277: 3003-3013.
38. Pungaliya C, Srinivasan J, Fox BW, Malik RU, Ludewig AH, et al. (2009) A shortcut to identifying small molecule signals that regulate behavior and development in Caenorhabditis elegans. Proc Natl Acad Sci U S A 106: 7708-7713.
39. Butcher RA, Fujita M, Schroeder FC, Clardy J, (2007) Small-molecule pheromones that control dauer development in Caenorhabditis elegans. Nat Chem Biol 3: 420-422.
40. Masuda M, Toriumi C, Santa T, Imai K, (2004) Fluorogenic derivatization reagents suitable for isolation and identification of cysteine-containing proteins utilizing high-performance liquid chromatography-tandem mass spectrometry. Anal Chem 76: 728-735.
41. McColl G, Killilea DW, Hubbard AE, Vantipalli MC, Melov S, et al. (2008) Pharmacogenetic analysis of lithium-induced delayed aging in Caenorhabditis elegans. J Biol Chem 283: 350-357.
42. Srinivasan J, Kaplan F, Ajredini R, Zachariah C, Alborn HT, et al. (2008) A blend of small molecules regulates both mating and development in Caenorhabditis elegans. Nature 454: 1115-1118.
43. Wilson MA, Shukitt-Hale B, Kalt W, Ingram DK, Joseph JA, et al. (2006) Blueberry polyphenols increase lifespan and thermotolerance in Caenorhabditis elegans. Aging Cell 5: 59-68.
44. Huang C, Xiong C, Kornfeld K, (2004) Measurements of age-related changes of physiological processes that predict lifespan of Caenorhabditis elegans. Proc Natl Acad Sci U S A 101: 8084-8089.
45. Liao VH, Yu CW, Chu YJ, Li WH, Hsieh YC, et al. (2011) Curcumin-mediated lifespan extension in Caenorhabditis elegans. Mech Ageing Dev 132: 480-487.
46. Ajmo JM, Liang X, Rogers CQ, Pennock B, You M, (2008) Resveratrol alleviates alcoholic fatty liver in mice. Am J Physiol Gastrointest Liver Physiol 295: G833-842.
47. Barger JL, Kayo T, Vann JM, Arias EB, Wang J, et al. (2008) A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS One 3: e2264.
48. Pearson KJ, Baur JA, Lewis KN, Peshkin L, Price NL, et al. (2008) Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab 8: 157-168.
49. Fonseca-Kelly Z, Nassrallah M, Uribe J, Khan RS, Dine K, et al. (2012) Resveratrol neuroprotection in a chronic mouse model of multiple sclerosis. Front Neurol 3: 84.
50. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, et al. (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444: 337-342.